BRIDGEBIO PHARMA INC. - COMMON STOCK

BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma

28 5月 2021 13:30:00 条件 Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

14 5月 2021 15:30:00 条件 Nasdaq GlobeNewswire

BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal Hyperplasia

14 5月 2021 06:30:00 条件 Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update

06 5月 2021 06:30:01 条件 Nasdaq GlobeNewswire

BridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven Conditions

13 4月 2021 06:45:00 条件 Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. and UC Davis Establish Collaboration to Transform Research into Potential Therapies for Genetically Driven Diseases

13 4月 2021 06:42:00 条件 Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. and Roswell Park Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Cancers

13 4月 2021 06:40:00 条件 Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. and Oregon Health & Science University Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Diseases

13 4月 2021 06:37:00 条件 Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. and The Lundquist Institute Collaborate to Advance Treatments for Genetically Driven Conditions and Cancers

13 4月 2021 06:35:00 条件 Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. and GlycoNet Initiate Collaboration to Discover Potential Treatments for Genetic Diseases through Glycomics Research

13 4月 2021 06:32:00 条件 Nasdaq GlobeNewswire